NASDAQ:BGNE

BeiGene Competitors

$300.65
+0.34 (+0.11 %)
(As of 04/14/2021 04:42 PM ET)
Add
Compare
Today's Range
$299.25
Now: $300.65
$307.52
50-Day Range
$289.22
MA: $323.41
$355.96
52-Week Range
$136.48
Now: $300.65
$388.97
Volume163,994 shs
Average Volume309,486 shs
Market Capitalization$27.53 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.91

Competitors

BeiGene (NASDAQ:BGNE) Vs. GSK, ZTS, VRTX, TAK, REGN, and ALXN

Should you be buying BGNE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to BeiGene, including GlaxoSmithKline (GSK), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TAK), Regeneron Pharmaceuticals (REGN), and Alexion Pharmaceuticals (ALXN).

GlaxoSmithKline (NYSE:GSK) and BeiGene (NASDAQ:BGNE) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Profitability

This table compares GlaxoSmithKline and BeiGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GlaxoSmithKline18.50%29.60%7.11%
BeiGene-569.22%-56.81%-39.93%

Analyst Ratings

This is a breakdown of recent ratings and price targets for GlaxoSmithKline and BeiGene, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GlaxoSmithKline34602.23
BeiGene21602.44

BeiGene has a consensus target price of $319.3750, indicating a potential upside of 6.23%. Given BeiGene's stronger consensus rating and higher probable upside, analysts plainly believe BeiGene is more favorable than GlaxoSmithKline.

Institutional and Insider Ownership

11.8% of GlaxoSmithKline shares are owned by institutional investors. Comparatively, 60.7% of BeiGene shares are owned by institutional investors. 10.0% of GlaxoSmithKline shares are owned by company insiders. Comparatively, 9.0% of BeiGene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

GlaxoSmithKline has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.

Valuation and Earnings

This table compares GlaxoSmithKline and BeiGene's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GlaxoSmithKline$43.10 billion2.26$5.93 billion$3.1711.40
BeiGene$428.21 million64.29$-948,630,000.00($15.80)-19.03

GlaxoSmithKline has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than GlaxoSmithKline, indicating that it is currently the more affordable of the two stocks.

Summary

GlaxoSmithKline beats BeiGene on 8 of the 13 factors compared between the two stocks.

Zoetis (NYSE:ZTS) and BeiGene (NASDAQ:BGNE) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Profitability

This table compares Zoetis and BeiGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zoetis25.50%63.89%14.99%
BeiGene-569.22%-56.81%-39.93%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Zoetis and BeiGene, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zoetis06902.60
BeiGene21602.44

Zoetis presently has a consensus target price of $170.0833, indicating a potential upside of 4.29%. BeiGene has a consensus target price of $319.3750, indicating a potential upside of 6.23%. Given BeiGene's higher probable upside, analysts plainly believe BeiGene is more favorable than Zoetis.

Institutional and Insider Ownership

92.5% of Zoetis shares are owned by institutional investors. Comparatively, 60.7% of BeiGene shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 9.0% of BeiGene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Zoetis has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.

Valuation and Earnings

This table compares Zoetis and BeiGene's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$6.26 billion12.37$1.50 billion$3.6444.80
BeiGene$428.21 million64.29$-948,630,000.00($15.80)-19.03

Zoetis has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Summary

Zoetis beats BeiGene on 10 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and BeiGene (NASDAQ:BGNE) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Volatility and Risk

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.

Profitability

This table compares Vertex Pharmaceuticals and BeiGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
BeiGene-569.22%-56.81%-39.93%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Vertex Pharmaceuticals and BeiGene, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042112.88
BeiGene21602.44

Vertex Pharmaceuticals currently has a consensus price target of $293.1250, indicating a potential upside of 35.00%. BeiGene has a consensus price target of $319.3750, indicating a potential upside of 6.23%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Vertex Pharmaceuticals is more favorable than BeiGene.

Earnings & Valuation

This table compares Vertex Pharmaceuticals and BeiGene's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.56$1.18 billion$4.2950.61
BeiGene$428.21 million64.29$-948,630,000.00($15.80)-19.03

Vertex Pharmaceuticals has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.7% of BeiGene shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 9.0% of BeiGene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats BeiGene on 12 of the 15 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and BeiGene (NASDAQ:BGNE) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Volatility and Risk

Takeda Pharmaceutical has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.

Profitability

This table compares Takeda Pharmaceutical and BeiGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Takeda Pharmaceutical3.04%13.46%5.02%
BeiGene-569.22%-56.81%-39.93%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Takeda Pharmaceutical and BeiGene, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Takeda Pharmaceutical01002.00
BeiGene21602.44

BeiGene has a consensus price target of $319.3750, indicating a potential upside of 6.23%. Given BeiGene's stronger consensus rating and higher probable upside, analysts clearly believe BeiGene is more favorable than Takeda Pharmaceutical.

Earnings & Valuation

This table compares Takeda Pharmaceutical and BeiGene's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$30.20 billion1.78$407.02 million$1.789.58
BeiGene$428.21 million64.29$-948,630,000.00($15.80)-19.03

Takeda Pharmaceutical has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

3.4% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 60.7% of BeiGene shares are owned by institutional investors. 9.0% of BeiGene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Takeda Pharmaceutical beats BeiGene on 8 of the 14 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and BeiGene (NASDAQ:BGNE) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 60.7% of BeiGene shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 9.0% of BeiGene shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Regeneron Pharmaceuticals and BeiGene's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.56$2.12 billion$21.4722.41
BeiGene$428.21 million64.29$-948,630,000.00($15.80)-19.03

Regeneron Pharmaceuticals has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.

Profitability

This table compares Regeneron Pharmaceuticals and BeiGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
BeiGene-569.22%-56.81%-39.93%

Analyst Ratings

This is a summary of recent recommendations for Regeneron Pharmaceuticals and BeiGene, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051412.80
BeiGene21602.44

Regeneron Pharmaceuticals currently has a consensus price target of $637.2083, indicating a potential upside of 32.43%. BeiGene has a consensus price target of $319.3750, indicating a potential upside of 6.23%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Regeneron Pharmaceuticals is more favorable than BeiGene.

Summary

Regeneron Pharmaceuticals beats BeiGene on 13 of the 15 factors compared between the two stocks.

BeiGene (NASDAQ:BGNE) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Profitability

This table compares BeiGene and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BeiGene-569.22%-56.81%-39.93%
Alexion Pharmaceuticals16.32%23.16%14.76%

Earnings & Valuation

This table compares BeiGene and Alexion Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeiGene$428.21 million64.29$-948,630,000.00($15.80)-19.03
Alexion Pharmaceuticals$4.99 billion6.84$2.40 billion$9.7415.94

Alexion Pharmaceuticals has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

60.7% of BeiGene shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 9.0% of BeiGene shares are held by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BeiGene and Alexion Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BeiGene21602.44
Alexion Pharmaceuticals017512.30

BeiGene currently has a consensus target price of $319.3750, indicating a potential upside of 6.23%. Alexion Pharmaceuticals has a consensus target price of $153.8636, indicating a potential downside of 0.92%. Given BeiGene's stronger consensus rating and higher possible upside, research analysts plainly believe BeiGene is more favorable than Alexion Pharmaceuticals.

Volatility and Risk

BeiGene has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats BeiGene on 10 of the 15 factors compared between the two stocks.


BeiGene Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
GlaxoSmithKline logo
GSK
GlaxoSmithKline
1.1$36.13+0.2%$97.04 billion$43.10 billion11.12
Zoetis logo
ZTS
Zoetis
2.2$163.08+0.2%$77.65 billion$6.26 billion48.39Increase in Short Interest
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$217.13+0.5%$56.14 billion$4.16 billion27.42Analyst Report
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
1.3$17.06+0.4%$53.60 billion$30.20 billion56.87
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$481.16+0.9%$51.11 billion$7.86 billion17.59Analyst Report
News Coverage
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$155.29+1.0%$34.14 billion$4.99 billion36.28
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$42.12+1.6%$25.15 billionN/A0.00Increase in Short Interest
Analyst Revision
News Coverage
Genmab A/S logo
GMAB
Genmab A/S
1.4$34.67+0.1%$22.73 billion$804.57 million26.88Decrease in Short Interest
Analyst Revision
News Coverage
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$91.45+0.2%$20.53 billion$1.30 billion24.99Insider Selling
Catalent logo
CTLT
Catalent
1.7$109.91+0.8%$18.56 billion$3.09 billion70.01Unusual Options Activity
Analyst Revision
CureVac logo
CVAC
CureVac
0.7$102.61+6.8%$17.88 billionN/A0.00Analyst Upgrade
Gap Down
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$138.31+1.5%$15.98 billion$219.75 million-17.66
Zai Lab logo
ZLAB
Zai Lab
1.4$164.83+2.1%$14.29 billion$12.98 million-54.40Analyst Report
News Coverage
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$78.23+0.6%$14.14 billion$1.70 billion17.90
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$29.58+0.6%$13.90 billion$3.07 billion-51.89Analyst Report
Grifols logo
GRFS
Grifols
1.3$17.86+0.1%$12.27 billion$5.71 billion15.95Upcoming Earnings
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$10.88+1.1%$11.75 billion$16.89 billion-2.96Decrease in Short Interest
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$30.26+1.5%$10.60 billion$8.60 billion-5.55
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.5$63.08+0.6%$10.43 billion$2.32 billion52.13News Coverage
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$36.95+1.5%$9.52 billionN/A0.00Increase in Short Interest
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$166.37+1.8%$9.20 billion$2.16 billion52.48Analyst Report
United Therapeutics logo
UTHR
United Therapeutics
1.5$202.78+1.7%$8.88 billion$1.45 billion19.18Analyst Report
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$55.75+2.1%$8.13 billion$40.56 million-16.35Analyst Report
News Coverage
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$161.46+1.0%$8.09 billion$3.34 million-20.97
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$107.97+1.3%$7.14 billion$103.71 million-24.59Analyst Revision
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.36+0.2%$6.83 billion$311.33 million-126.95Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$124.24+0.5%$6.71 billion$14.98 million-15.13Analyst Downgrade
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.17+4.8%$6.64 billion$87.99 million-79.96Unusual Options Activity
News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.57+0.2%$6.28 billion$150,000.00-21.02
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.83+1.8%$5.79 billion$1.12 billion87.15
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$73.43+4.7%$5.56 billion$380.83 million-9.39
Allakos logo
ALLK
Allakos
1.7$107.59+2.9%$5.55 billionN/A-39.27
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$96.86+3.9%$5.39 billion$66.51 million17.87Analyst Report
News Coverage
Perrigo logo
PRGO
Perrigo
2.5$40.38+0.6%$5.36 billion$4.84 billion-672.89
Schrödinger logo
SDGR
Schrödinger
1.3$78.15+3.4%$5.29 billion$85.54 million0.00
Galapagos logo
GLPG
Galapagos
1.3$80.48+2.7%$5.13 billion$1.00 billion-12.19Analyst Report
Gap Down
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$54.58+4.8%$4.73 billionN/A0.00Analyst Report
Increase in Short Interest
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.80+2.7%$4.52 billionN/A-6.10Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.19+1.5%$4.25 billion$204.89 million-36.49
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$75.67+4.9%$4.20 billion$6.87 million-7.31Analyst Report
Unusual Options Activity
Analyst Revision
News Coverage
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.64+1.8%$4.01 billion$806.43 million-9.58Analyst Report
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$74.47+2.3%$3.88 billion$1.11 billion23.95Analyst Report
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$75.90+1.4%$3.72 billionN/A-21.62Analyst Report
High Trading Volume
News Coverage
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$53.36+2.4%$3.71 billion$117.91 million-10.82
I-Mab logo
IMAB
I-Mab
1.2$55.09+9.9%$3.57 billion$4.31 million-1.91Increase in Short Interest
LEGN
Legend Biotech
1.2$26.76+1.1%$3.49 billion$64.39 million0.00Decrease in Short Interest
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.14+2.4%$3.41 billion$114.62 million-7.72Analyst Report
News Coverage
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$44.48+5.0%$3.40 billionN/A-5.99News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.90+1.2%$3.33 billion$306.98 million-6.85
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.28+3.2%$3.30 billion$339.08 million-12.37Analyst Report
News Coverage
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.